

# RESOURCE DEVELOPMENT AWARD

Leveraging Technology for Product Development



Without appropriate cell lines and animal models, progress in our understanding of neurofibromatosis (NF) and Schwannomatosis or in the development and testing of new treatment strategies would be severely impaired. The **Neurofibromatosis Research Program (NFRP)** recognizes the critical need for improved resources to advance these fields. The Resource Development Award was established to support product-driven studies aimed at the development of critical resources and essential tools necessary to advance basic research. These tools may include, but are not limited to, animal models, antibodies, cell lines, assays, or other innovative resources that would be made available to the scientific community.

Funding for these awards can be requested for a maximum of \$133,000 for direct costs over a 2 year performance period, plus indirect costs as appropriate. Due to the nature of this award, preliminary data are not required but may be included, if available, to address the feasibility of the resource to be developed. Additionally, submission of a resource distribution plan is required. Peer review will emphasize the proposed product, research strategy, the potential to make an important contribution to the NF/Schwannomatosis fields, and the expertise of the applicant and research team. See the Program Announcement for additional criteria.

Proposals Are Due By:  
**April 25, 2006**

*This document is a synopsis of details specific to the NFRP Resource Development Award. A detailed description of this award mechanism along with specific evaluation criteria, submission requirements, and deadlines are available in the [FY06 NFRP Resource Development Award Program Announcement](#) found at:*

**<http://cdmrp.army.mil>**

# THERAPEUTIC DEVELOPMENT AWARD

Accelerating the Discovery and Evaluation of Treatments for  
Neurofibromatosis (NF) and Schwannomatosis

The Therapeutic Development Award supports product-driven studies in:

- ▶ Development of screens or preclinical model systems to identify or evaluate potential therapeutics for NF1, NF2, or Schwannomatosis
- ▶ Preclinical pharmacological or pharmacokinetic testing of new or existing therapeutic agents in models of NF1, NF2, or Schwannomatosis

The vision of the **Neurofibromatosis Research Program (NFRP)** is to decrease the impact of these diseases. New, more effective treatments will alleviate suffering and enhance the quality of life for individuals with these disorders. The Therapeutic Development Award was established to accelerate the progression of novel treatment strategies for NF and Schwannomatosis from bench to bedside. This award may also support hypothesis-driven studies that focus on the development of clinical therapeutics.

Biotechnology and pharmaceutical companies are encouraged to submit proposals and leverage their own resources to complement NFRP funding and support the preclinical development process. Likewise, the formation of multi-institutional consortia is also encouraged, as the collaborative efforts of multidisciplinary groups are likely to lead to more rapid introduction of improved therapies into the clinical setting.

Funding for these awards can be requested for up to 3 years. There is no total dollar amount restriction; however, the NFRP will give priority to smaller-scale, cost-efficient projects with well-defined endpoints and studies conducted by multidisciplinary consortia. Peer review will emphasize research strategy, the potential to make an important contribution to the NF/Schwannomatosis fields, and the expertise of the applicant. See the program announcement for additional criteria.

Proposals Are Due By:  
**April 25, 2006**

*This document is a synopsis of details specific to the NFRP Therapeutic Development Award. A detailed description of this award mechanism along with specific evaluation criteria, submission requirements, and deadlines are available in the [FY06 NFRP Therapeutic Development Award Program Announcement](#) found at:*

<http://cdmrp.army.mil>

